Jardiance + insulin guidance
A new guide confirms the SGLT2 inhibitor Jardiance can be taken with insulin in type 2 diabetes—provided there’s close medical supervision to manage hypoglycemia risk and individual dose adjustments. This is practical intel for people considering combination therapy and for analysts modeling real‑world medication regimens. (icgi.org)
A randomized add‑on study cited in the Jardiance prescribing information enrolled 494 adults inadequately controlled on insulin and evaluated empagliflozin as adjunctive therapy over 78 weeks. (dailymed.nlm.nih.gov) In a separate randomized trial of obese, inadequately controlled T2D patients on multiple daily insulin injections (n≈563 across arms), empagliflozin 10 mg and 25 mg produced adjusted HbA1c reductions of −0.94% and −1.02% at 18 weeks and allowed lower total daily insulin doses by week 52 (baseline mean insulin ≈92 IU/day). (diabetesjournals.org) Pooled analyses from EMPA‑REG and related programs reported that empagliflozin reduced new insulin starts (7.1% vs 16.4% with placebo; adjusted HR 0.40) and increased the likelihood of sustained ≥20% reductions in total daily insulin dose among insulin‑treated participants. (dom-pubs.onlinelibrary.wiley.com) The U.S. label and DailyMed list the recommended starting dose as 10 mg once daily with an option to increase to 25 mg, and instruct clinicians to assess and correct volume depletion before initiation. (accessdata.fda.gov) Regulatory and manufacturer safety language highlights three actionable risks: higher hypoglycemia rates when empagliflozin is combined with insulin or insulin secretagogues (insulin dose reduction may be required), risk of diabetic ketoacidosis particularly in type 1 or ketosis‑prone patients, and ineffective or not‑recommended use when eGFR <30 mL/min/1.73 m2. (pro.boehringer-ingelheim.com) Analysts modeling real‑world regimens should incorporate trial‑level effects—trial sample sizes (e.g., 494 in the insulin add‑on study), the observed 60% relative reduction in new insulin initiation in some cohorts, and documented probabilities of insulin dose down‑titration—alongside label constraints (starting dose, eGFR cutoff) when projecting treatment pathways or budget impacts. (dailymed.nlm.nih.gov)
